Hana Biosciences initiated by Griffin at buy

Hana Biosciences Inc. coverage was initiated by Griffin Securities Inc. analyst Chrystyna Bedrij with a buy rating and a price target of $8 to $12. South San Francisco-based Hana Biosciences focuses on treatments for cancer and immunological diseases with several candidates in development. Hana Biosciences shares Monday rose 13 cents, or 8.03%, to $1.75 on volume of 357,325 shares versus the three-month running average of 9,396.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.